PASG News
Archived Headlines
- IPO Weekly Recap: Yes, the IPO Market has caught the coronavirus 02/28/20
- Gene therapy developer Passage Bio prices upsized IPO at the $18 high end 02/27/20
- Preclinical biotech Passage Bio increases IPO share offering by 35%, now plans to raise $170 million 02/27/20
- US IPO Week Ahead: One biotech to close out February 02/21/20
- Preclinical biotech Passage Bio sets terms for $126 million IPO 02/18/20
See more
US IPO Week Ahead: Chinese EV's billion-dollar deal closes out summer in a 2 IPO week
Two IPOs and two SPACs are scheduled to go public in the week ahead. Chinese EV maker Xpeng (XPEV) is leading summer's last wave with a billion-dollar deal. Xpeng (XPEV) plans to raise $1.0 billion at an $8.8 billion market cap....read more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more
US IPO Week Ahead: The IPO market shutdown continues with another quiet week
There are no IPOs scheduled for the week ahead as the IPO market shutdown continues. Two SPACs may price on a day-to-day basis. Renaissance Capital will be releasing its 1Q20 Quarterly Reviews for both the US and the Global IPO...read more
Wave of IPOs file in spite of market turmoil
A wave of 6 IPOs and 5 SPACs submitted initial filings over the past week, despite the stock market having its worst week since 2008. Most filed on Friday, meaning they will be able to launch as soon as Monday, March 16, and schedule IPOs for the last week...read more